Takeda fails to get class decertified in US Amitiza antitrust case
( September 14, 2026, 20:31 GMT | Official Statement) -- MLex Summary: Takeda Pharmaceuticals was denied a motion to decertify a class of direct purchasers accusing it of delaying a generic version of the drug Amitiza. District Judge Myong J. Joun found that Takeda failed to carry its burden of showing that the jury's finding concerning the generic-entry date, the inclusion of the assignee class members, or the lead plaintiff's adequacy or typicality constitutes a post-certification development warranting decertification. See attached file....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.